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OmphaloceleWe report that the disruption of bidirectional signaling between ephrin-B2 and EphB receptors impairs
morphogenetic cell–cell septation and closure events during development of the embryonic midline. A novel
role for reverse signaling is identiﬁed in tracheoesophageal foregut septation, as animals lacking the
cytoplasmic domain of ephrin-B2 present with laryngotracheoesophageal cleft (LTEC), while both EphB2/
EphB3 forward signaling and ephrin-B2 reverse signaling are shown to be required for midline fusion of the
palate. In a third midline event, EphB2/EphB3 are shown to mediate ventral abdominal wall closure by acting
principally as ligands to stimulate ephrin-B reverse signaling. Analysis of new ephrin-B26YFΔV and ephrin-B2ΔV
mutants that speciﬁcally ablate ephrin-B2 tyrosine phosphorylation- and/or PDZ domain-mediated signaling
indicates there are at least two distinct phosphorylation-independent components of reverse signaling. These
involve both PDZ domain interactions and a non-canonical SH2/PDZ-independent form of reverse signaling
that may utilize associations with claudin family tetraspan molecules, as EphB2 and activated ephrin-B2
molecules are speciﬁcally co-localized with claudins in epithelia at the point of septation. Finally, the
developmental phenotypes described here mirror common human midline birth defects found with the
VACTERL association, suggesting a molecular link to bidirectional signaling through B-subclass Ephs and
ephrins..edu (M. Henkemeyer).
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VACTERL is used to denote a non-random association of human
embryonic malformations. The deﬁning features of VACTERL include
vertebral defects (V), anorectal malformations (A), cardiac anomalies
(C), tracheoesophageal septation defects (TE), renal dysplasia (R), and
limb abnormalities (L) (Temtamy and Miller, 1974). Cases of VACTERL
are deﬁned as presenting with two or more of these anomalies, and
most of the 1 in 5000 live births associated with VACTERL have only
diads or triads (Rittler et al., 1996). Additional congenital anomalies are
also observed in VACTERL patients outside of the deﬁning features,
including hypospadias, cleft palate, neural tube defects, and omphalo-
cele (Botto et al., 1997; Rittler et al., 1996). Evidence has built for a
genetic basis behind VACTERL; however, a molecular understanding
of the association remains rudimentary (Aynaci et al., 1996; Nezarati
and McLeod, 1999). At present, the only VACTERL association animal
models are mice impaired in Shh signaling (Shh, Gli deﬁcient animals),
knockouts for Foxf1, Noggin, or Sox2, or animals treated in utero with
the anthracycline antibiotic, adriamycin (Kim et al., 2001; Shaw-Smith,
2009).The Eph receptor family represents the largest collection of
transmembrane receptor tyrosine kinases, while the ephrins are their
membrane-bound ligands. A-subclass ephrins are attached to the outer
leaﬂet of the plasma membrane by a GPI-linkage, while B-subclass
ephrins possess a single-pass transmembrane domain and a short
cytoplasmic tail. In general, EphA receptors can promiscuously bind to
A-subclass ephrins and EphB receptors can similarly bind to B-subclass
ephrins, although subclass crosstalk has been documented (Bergemann
et al., 1998; Davis et al., 1994; Himanen et al., 2004). As both Ephs and
ephrins aremembrane anchored, signaling by thesemolecules occurs at
sites of cell–cell contact. Signal transduction between Ephs and ephrins
is atypical from other receptor/ligand pairs in that the potential exists
for bidirectional signaling into both the Eph and ephrin expressing cells
(Henkemeyer et al., 1996; Holland et al., 1996). Signaling into cells
expressingEphreceptors (forward signaling)occurs principally through
activation of its intracellular tyrosine kinase catalytic domain which
leads toautophosphorylation, coupling to Src homology2 (SH2)domain
proteins, and phosphorylation of downstream substrates (Kullander
and Klein, 2002). Eph receptors can also form other protein–protein
associations, notably through their sterile-alpha (SAM) and C-terminal
PDZ-binding motifs. Conversely, signaling into cells expressing B-
subclass ephrins (reverse signaling) also leads to the phosphorylation
of conserved tyrosine residues on the cytoplasmic tail of the ephrin-B
molecule and the subsequent docking to SH2 adaptor proteins such as
Grb4/Nck-β (Cowan and Henkemeyer, 2001; Xu and Henkemeyer,
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motif. The bidirectional nature of Eph/ephrin signaling complicates
studies of these molecules. Therefore, to precisely elucidate the
physiological role of a given Eph or ephrin it is necessary to dissect
both the forward and reverse signaling contributions of that particular
molecule.
Beyond their potential for bidirectional signaling, the Ephs and
ephrins are further unique with respect to the targets of their signal
transduction. Whereas most tyrosine kinase-mediated signaling
events ultimately target the nucleus to regulate transcription, the
Ephs and ephrins appear to principally exert control over cytoskeletal
dynamics. This control is achieved through the activation of secondary
molecules linked to cytoskeletal control, many of which ultimately
regulate small Rho family GTPases (Egea and Klein, 2007; Noren and
Pasquale, 2004). Given this ability to fundamentally alter the structure
of the cell in response to cell–cell contact, it is not surprising that Ephs
and ephrins are utilized as key regulators of cell migration/
differentiation events throughout development, as typiﬁed by their
well-deﬁned physiological roles in axon pathﬁnding (Flanagan and
Vanderhaeghen, 1998; Wilkinson, 2001), angiogenic remodeling
(Cowan et al., 2004;Wang et al., 1998), and neural crest cell migration
(Davy et al., 2004; Smith et al., 1997).
While the majority of studies implicate Eph–ephrin signaling in
cell migration and axon pathﬁnding by inducing repulsion, there is
some evidence to suggest these molecules may also function in the
opposite manner to induce cell adhesion responses. This evidence
includes the characterization of apparent cell adhesion defects in
the palate, urethra, cloaca, and neural tube in Eph/ephrin mutant
animals (Dravis et al., 2004; Holmberg et al., 2000; Orioli et al., 1996),
Eph–ephrin mediated axon guidance events that appear to utilize
attraction outcomes following axon-cell contact instead of the
canonical repulsion seen most often with the Ephs and ephrins
(Eberhart et al., 2004; Hindges et al., 2002), and cell-based studies
indicating positive outgrowth of cytoskeletal structures in response to
Eph–ephrin signaling activation instead of the more typical cytoskel-
etal collapse associated with these molecules (Hansen et al., 2004;
Huynh-Do et al., 1999; Stein et al., 1998). Here we focus on describing
new roles for these molecules that also appear consistent with cell–
cell adhesion responses.
Using a variety of EphB/ephrin-B mutant alleles, we identify
requirements for ephrin-B2 and EphB2 in septation and closure
events at the embryonicmidline in the developing foregut, palate, and
ventral bodywall. The LTEC, cleft palate, and omphalocele phenotypes
mimic VACTERL association birth defects. Combined with previous
studies reporting the involvement of the Ephs and ephrins in other
VACTERL-like developmental malformations (Compagni et al., 2003;
Cowan et al., 2004; Davy and Soriano, 2007; Dravis et al., 2004;
Holmberg et al., 2000), we now ﬁnd a near complete overlap between
Eph/ephrin-associated developmental defects and the malformations
of VACTERL. This leads us to propose EphB/ephrin-B signaling as a
molecular basis for VACTERL association and to highlight the use of
EphB/ephrin-B deﬁcient mice for VACTERL research.
Results
To characterize roles for ephrin-B2 and EphB2 in midline
development, we utilized (1) ephrin-B2lacZ mice, in which the cyto-
plasmic domain of ephrin-B2 has been replaced by β-galactosidase
(β-gal) to abolish reverse signaling while leaving intact its ligand-like
ability to bind Eph receptors and activate forward signaling in
the same fashion as native ephrin-B2 (Supplemental Fig. 1), and
(2) EphB2lacZ mice, in which the majority of the EphB2 cytoplasmic
domain has been replaced by β-gal to block forward signaling by this
molecule while leaving intact its ligand-like ability to bind ephrins
and stimulate reverse signaling (Dravis et al., 2004; Henkemeyer
et al., 1996). The ephrin-B2lacZ allele has been used successfullyin the past to identify a distinct ligand-only role for ephrin-B2 in
angiogenesis (Cowan et al., 2004) and axon guidance (Williams et al.,
2003), as well as clear receptor roles in urorectal development (Dravis
et al., 2004), anterior commissure axon guidance and cardiac
development (Cowan et al., 2004), and inner ear ﬂuid dynamics
(Dravis et al., 2007). The ephrin-B2lacZ allele, which is homozygous
viable throughout embryonic development, has proven to be very
useful for understanding the functions of ephrin-B2 reverse signaling,
given that ephrin-B2−/− null mutants are early embryonic lethal due
to vascular defects caused by the loss of EphB4 forward signaling that
preclude analysis of later development (Wang et al., 1998). Likewise,
the EphB2lacZ allele has been used to identify ligand-only roles for
EphB2 in axon guidance (Birgbauer et al., 2000; Henkemeyer et al.,
1996), and receptor roles for EphB2 in axon guidance (Cowan et al.,
2000; Hindges et al., 2002), vestibular development (Cowan et al.,
2000), and urorectal development (Dravis et al., 2004).
Ephrin-B2 reverse signaling mediates midline septation of the foregut
Initial studies of ephrin-B2lacZ mice indicated that a loss of ephrin-
B2 reverse signaling leads to neonatal lethality, with defects in cardiac
development and midline adhesion of the urethra and anorectum
(Cowan et al., 2004; Dravis et al., 2004). Because of the urorectal/
hindgut defects, ephrin-B2lacZ embryos were also examined to
determine if septation of the foregut was similarly affected. This
revealed that 47% (n=15) of late stage embryonic day 18 (E18)
ephrin-B2lacZ/lacZ mutants exhibited defects in tracheoesophageal (TE)
septation as evidenced by common, unseptated foregut. The defects
observed in the ephrin-B2lacZ/lacZ embryos appearedwith a phenotypic
range of moderate, in which a septum was visible but had failed to
extend to the rostral apex, to severe, in which no septum was
detected, and only unseptated foregut was present rostral to the
bronchi (Fig. 1A). Sections taken of earlier E14.5 embryos showed the
same defect in foregut septation; distinct trachea and esophagus were
visible in the wild-type (WT) embryo, while an ephrin-B2lacZ/lacZ
littermate showed only unseptated foregut (Fig. 1B). The failure of
foregut septation in ephrin-B2lacZ/lacZ mutants results in morpholog-
ical abnormalities in the unseptated trachea, as visualized by the
appearance of disorganized cartilage rings in the mutants (Fig. 1C).
We next examined ephrin-B2lacZ embryos at earlier stages of
development and found that homozygotes collected at E10.5 also
showed defective TE septation. While ephrin-B2lacZ/+ embryos
appeared normal and showed a common rostral foregut that septated
into separate tracheal and esophageal endoderm caudally (Fig. 2A),
ephrin-B2lacZ/lacZ littermates showed no signs of TE septation all the
way down to the terminal caudal point of the foregut, despite
otherwise normally patterned foregut endoderm (Fig. 2B).
The discovery of TE ﬁstula in ephrin-B2lacZ mutants suggests that
reverse signaling through the cytoplasmic domain of ephrin-B2 is
necessary for proper septation of the foregut. However, the ephrin-
B2lacZ allele is not able to answer which Eph receptors are involved in
activating these signals. To address this, Eph receptor compound null
animals were generated, as these genes can show redundant
functions. However, analysis of EphB2;EphB3, EphB2;EphB3;EphA4,
and EphB1;EphB2;EphB3;EphA4 compound knockouts did not reveal
any defects in TE septation. This suggests at least one additional Eph
receptor (i.e., EphB4 or EphB6) may be paired with ephrin-B2 in
foregut septation.
X-gal stains on foregut sections from ephrin-B2lacZ embryos were
carried out to document expression of the ephrin-B2–β-gal fusion
protein, which provides a high signal-to-noise ratio reporter of
protein expression (Fig. 2). The data showed ephrin-B2 is expressed
along the length of the foregut endoderm, and appears to be most
highly expressed in the epithelia of the foregut destined to become
esophagus as well as in the mesenchyme surrounding the esophagus.
Ephrin-B2 is notably present at the site of TE septation in ephrin-
Fig. 1. Failed midline septation of the foregut in ephrin-B2lacZ mutants. (A) H&E stained sagittal sections from E18 WT or ephrin-B2lacZ/lacZ littermates. In the WT (left), a septum is
discernable (arrow), separating the esophagus (E) from the trachea (T). Defects in septation in the mutants were classiﬁed as moderate, where a septum is visible but failed to fully
extend rostrally (arrow, middle); or severe, where no septum formed (*, right). (B) H&E stained transverse sections from E14.5WT and ephrin-B2lacZ/lacZ littermates. In theWT (left),
septation occurred to produce distinct esophageal (E) and tracheal (T) endoderm. Equivalent section of a mutant (right) revealed an unseptated foregut (TE). (C) H&E stained
coronal sections of E18WT and ephrin-B2lacZ/lacZ littermate embryos.While a normal banding of the cartilage rings surrounding the trachea is observed in theWT (left), mutants with
failed tracheoesophageal septation present with disorganized cartilage bands (right).
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ephrin-B2lacZ/lacZ mutants (Fig. 2, Supplemental Fig. 2A). Indirect
immunoﬂuorescence (IF) using a pan-ephrin-B antibody on WT
embryos shows a similar expression proﬁle as the X-gal stains for the
ephrin-B2–β-gal fusion protein (Fig. 2D).
While the Eph receptors involved in foregut septation are
unknown, we reasoned that EphB3 was likely involved based on its
role in cell adhesion events during hindgut septation (Dravis et al.,
2004). Unfortunately, conventional methods to examine EphB3
expression by mRNA in situ hybridization or immunohistochemistry
have not provided satisfactory results, so a BAC transgenic animal was
generated that expresses the reverse tetracycline transactivator,
rtTA2S-M2 (Urlinger et al., 2000), under control of EphB3 promoter
sequences (Villasenor et al., in preparation). Tg-BAC-EphB3-rtTA
transgenic mice were crossed to a TRE-lacZ reporter line (Ludwig et
al., 2004) and dox-induced embryos hemizygous for both transgenes
were collected and stained with BluO-gal to reveal β-gal expressing
cells. This showed that EphB3 is expressed in the mesenchymal cells
coming into contact with epithelial cells at the site of TE septation
(Fig. 2E). BluO-gal stains on foregut tissue from EphB2lacZ/+ animals
indicated expression of EphB2 on epithelia at the point of septation
(Supplemental Fig. 2B). The expression data strongly indicate that
EphB2 and EphB3 likely participate in foregut septation.
EphB:ephrin-B bidirectional signaling in midline formation of the palate
EphB2;EphB3 compound null mice exhibit a cleft palate phenotype
that is not observed in EphB2 or EphB3 single mutants (Orioli et al.,
1996; Risley et al., 2009). To determine if EphB2 is acting as a receptor
to transduce forward signals or as a ligand to activate reverse
signals important in palate development, both EphB2− null and
EphB2lacZ C-terminal truncation mutants were utilized. Histological
analysis at E18.5 revealed that 41% of EphB2lacZ/lacZ;EphB3−/− and 15%
of EphB2−/−;EphB3−/− compound mutants exhibited severe cleftpalates (Table 1). Finding cleft palates with the EphB2lacZ allele indicates
that EphB forward signaling is important in the development of this
midline structure. The increase in penetrance to 41% further suggests
involvement of more than EphB2 and EphB3 in palate development, as
the dominant negative effect seen here with the EphB2lacZ allele is best
explained by the ability of the intracellular truncated EphB2–β-gal
fusion protein to disrupt forward signaling of other co-expressed Eph
receptors (Cowan et al., 2000; Hindges et al., 2002).
To determine if ephrin-B2 is involved in palate formation, embryos
carrying the ephrin-B2lacZ allele were examined. Histological analysis
revealed that 26% of ephrin-B2lacZ/lacZ homozygotes and 7% of ephrin-
B2lacZ/+ heterozygotes showed a severe cleft palate (Table 2, Fig. 3A).
This indicates that ephrin-B2 is involved inpalate fusion and that reverse
signaling through this molecule is important for this process, which is
consistent with the conclusion from recent in vitro analyses of Eph–
ephrin signaling in palatal shelf fusion (SanMiguel et al., 2011). Coupled
with the aforementioned EphB2;EphB3 results, the data indicate both
forward signaling throughEphBreceptors and reverse signaling through
ephrin-B2 are important for midline closure of the palate. This
involvement of bidirectional signaling through both EphB and ephrin-
B mirrors a similar requirement for both forward and reverse signaling
in urorectal/hindgut midline development (Dravis et al., 2004).
The expression proﬁles of ephrin-B2 and EphB2 were examined
during palatal development. X-gal stains of ephrin-B2lacZ/+ embryos
revealed expression of ephrin-B2 throughout the mesenchyme of the
palatal shelf, as well as in the leading epithelia before adhesion and
fusion take place (Fig. 3B). Later, when adhesion has taken place,
ephrin-B2 is clearly visible on the multilayer epithelial seam, as well
as in the mesenchyme ﬂanking the midline site of adhesion. IF of
palatal shelves with an antibody against EphB2 revealed EphB2
expression in the mesenchyme and leading epithelia of the palatal
shelf at E13.5 (Fig. 3C). No signal was detected in control EphB2−/−
tissue (Fig. 3C). X-gal stains of EphB2lacZ/+ animals further showed
that as palatal shelf closure nears and as it occurs EphB2 expression
141C. Dravis, M. Henkemeyer / Developmental Biology 355 (2011) 138–151
Table 1
Incidence of cleft palate in EphB2;EphB3 compound mutants.
EphB2 mutation Background B2/B2;B3/B3 B2/+;B3/B3 +/+;B3/B3
EphB2− CD1 27 (4) 32 (1) NA
EphB2lacZ CD1 29 (12) 17 (2) NA
EphB2−/−;EphB3−/− or (EphB2lacZ/lacZ;EphB3−/−) males were intercrossed with EphB2
−/+;EphB3−/− females (or EphB2lacZ/+;EphB3−/−) and offspring collected at E18.5.
Animals with cleft palate are in parentheses.
Table 2
Incidence of cleft palate in ephrin-B2lacZ mutants.
Background ephrin-B2lacZ/lacZ ephrin-B2lacZ/+ ephrin-B2+/+
129/CD1 35 (9) 59 (4) N40 (0)
Ephrin-B2lacZ/+ heterozygotes were intercrossed and offspring collected at E18.5.
Animals with cleft palate are in parentheses.
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takes place (Fig. 3C).
To investigate EphB3 expression, a BAC transgenic line was
generated that expresses eYFP under EphB3 promoter sequences,
termed Tg-BAC-EphB3-YFP. IF for GFP to detect expression of eYFP
showed that EphB3 is expressed at the leading mesenchyme of the
palatal shelves (Fig. 3D). EphB3 expression was further examined in
X-gal stains of palatal shelves from dox treated embryos hemizygous
for the Tg-BAC-EphB3-rtTA and TRE-lacZ transgenes. This also showed
EphB3 expression in the mesenchyme of the palatal shelves at E13.5
and that this expression shifts from the mesenchyme to epithelia as
palatal shelf closure nears at E14.5 (Fig. 3D). To summarize these
expression data, remarkably the proﬁles for EphB2, EphB3, and
ephrin-B2 appear nearly identical to each other during formation of
the palate.
Based on the individual expression studies taken for ephrin-B2 and
the EphB receptors, we speculated that these molecules were likely
co-expressed at the site of cell–cell adhesion as the palatal shelves
meet and fuse at the midline. To address this, double IF analysis on
ephrin-B2lacZ/+ embryos using antibodies against EphB2 and β-gal
was performed. This revealed that EphB2 and ephrin-B2 are co-
expressed on the midline epithelia where palatal shelf closure occurs
(Fig. 3E). Interestingly, this mimics the previous ﬁnding of co-
expression in adhering midline epithelial cells at the site of
urorectal/hindgut septation (Dravis et al., 2004).
EphB2/EphB3 activate reverse signaling for midline closure of the ventral
body wall
While analyzing palate and foregut defects in the EphB receptor
mutant mice, it was noticed that 39% of EphB2−/−;EphB3−/−
compound nulls exhibited a failure in midline closure of the
abdominal wall (Fig. 4A, Table 3), as brieﬂy reported before (Orioli
et al., 1996). The ventral midline defect in these mice resembles the
birth defect omphalocele, in which visceral organs are herniated. This
defect appears to be dependent on the genetic background of the
mouse, as omphalocele was detected in the inbred 129 strain, but not
in mice of a CD1 background. To determine where EphB2 is expressed
during ventral midline closure of the abdominal wall, BluO-gal stains
on whole-mounted EphB2lacZ/+ embryos were performed (Fig. 4B).
Expression of EphB2 was detected at E13.5 in cells at the ventral
midline where abdominal closure takes place and at E15.5 was
localized to the terminal closure spot of the umbilical ring. To
determine if forward signaling through EphB2 participates in ventralFig. 2. Ephrin-B2 and EphB3 expression during foregut septation. (A, B) Serial X-gal stained
septation in the ephrin-B2lacZ/+ embryo proceeds from common foregut (left), to septating f
(right). Septation of the foregut in the homozygous mutant failed to occur (left), caudal to w
the emerging bronchi is present at the very caudal end of the foregut (right). X-gal stain s
foregut at septation, with higher levels of expression detected at the future esophageal po
esophagus. (C) Serial X-gal stained sections from an E11.5 ephrin-B2lacZ/+ embryo. Similar to
future esophageal endoderm. Ephrin-B2 is also present on the endoderm and ﬂanking me
septation fromWT embryo stained at E10.5 and E11.5 with a pan-ephrin-B antibody. Ephrin-
the endoderm of the foregut. (E) BluO-gal stained coronal sections from a Tg-BAC-EphB3-rtT
B2, EphB3 is highly expressed in themesenchyme ﬂanking the future point of septation (*, le
an adjacent caudal section (right).body wall closure, the penetrance of this phenotype was investigated
using the EphB2lacZ allele, revealing that only 9% of EphB2lacZ/lacZ;
EphB3−/− animals exhibited omphalocele (Table 3). Given these data,
and taking into account the reports that ephrin-B1 knockouts also
have incompletely penetrant omphalocele (Compagni et al., 2003;
Davy et al., 2004), it appears that EphB2 and EphB3 act primarily as
ligands to stimulate ephrin-B1 reverse signaling during midline
closure of the ventral body wall.
Ephrin reverse signaling is activated at sites of septation
Eph–ephrin bidirectional signaling occurs at sites of cell–cell
contact, which leads to clustering of the molecules into tetramers and
higher order aggregates, along with tyrosine phosphorylation of their
intracellular domains.We therefore sought to addresswhere ephrin-B
reverse signaling was activated during these midline events by using
two different antibodies that recognize phosphorylated tyrosine
residues within the conserved ephrin-B cytoplasmic domain. IF on
sections of septating foregut at E10.5 showed that while some ephrin-
B is tyrosine phosphorylated in the mesenchyme ﬂanking the point of
septation, the most striking tyrosine phosphorylation of ephrin-B is
detected along the septating endoderm (Fig. 5A). Adjacent sections
treated with lambda phosphatase conﬁrmed the phospho-speciﬁc
activity of the antibodies. These data localize ephrin-B tyrosine
phosphorylation to midline septation in the foregut.
Adjacent palatal shelf sections from an E14 ephrin-B2lacZ/+ embryo
were similarly probed with an antibody against β-gal to detect
ephrin-B2 and phospho-ephrin-B antibodies to determine where
ephrin-B2 was phosphorylated. While the β-gal antibody labeled the
leading epithelia of the palatal shelf as well as the ﬂanking mesoderm,
the phospho-ephrin antibodies indicated that only ephrin-B2 in the
leading epithelia of the palatal shelf was tyrosine phosphorylated
(Fig. 5B). Double IF with EphB2 and phospho-ephrin antibodies co-
localized EphB2 with tyrosine-phosphorylated ephrin-B2 (Fig. 5C).
These data importantly localize ephrin-B2 reverse signaling to
epithelia at the point of cell adhesion and closure in the developing
palate.
Ephrin-B2 PDZ domain interactions contribute to midline septation
Having characterized roles for ephrin-B2 reverse signaling in
midline septation, we next sought to determine which signaling
avenues of the ephrin-B2 cytoplasmic tail are utilized for these
morphogenetic events. To address this, two new ephrin-B2 alleles
were created, ephrin-B2ΔV (Fig. 6, Supp. Fig. 2) and ephrin-B26YFΔV
(Thakar et al., unpublished data). In ephrin-B2ΔV mice, the codon fortransverse sections from E10.5 ephrin-B2lacZ/+ and ephrin-B2lacZ/lacZ littermates. Normal
oregut (middle), to septated foregut showing separated esophagus (E) and trachea (T)
hich only unseptated foregut remains (middle). A ﬁstula (TE) between esophagus and
hows expression of the ephrin-B2–β-gal fusion protein (blue) in the endoderm of the
le of the foregut. Ephrin-B2 is also found in the mesenchyme surrounding the future
E10.5, ephrin-B2 is highly expressed in the mesenchyme and epithelia associated with
senchyme at the point of septation (arrows). (D) Coronal sections capturing foregut
B is present in the mesenchyme associated with the future esophageal endoderm and in
A; TRE-lacZ embryo treated with dox to visualize EphB3 expression (blue). Like ephrin-
ft), where lateral folds will invaginate into the foregut andmeet at the midline as seen in
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interaction of ephrin-B2 with PDZ domain-containing proteins. In
ephrin-B26YFΔV mice, the six tyrosines of the ephrin-B2 cytoplasmic
domain were changed to phenylalanine to prevent tyrosine phos-
phorylation of ephrin-B2 and the same C-terminal valine was deleted,
resulting in the loss of interactions with both SH2 and PDZ domain-
containing proteins (Fig. 6B). The cell surface localization of these
molecules and their inability to interact with PDZ domain-containing
proteins have been demonstrated (Thakar et al., unpublished data;
Makinen et al., 2005), while proper expression of ephrin-B2ΔV was
conﬁrmed by immunoblot analysis (Supplemental Fig. 3).
Interestingly, neither ephrin-B2ΔV/ΔV nor ephrin-B26YFΔV/6YFΔV
mutant mice present with defects in urorectal, tracheoesophageal,
or palatal development. Remarkably, while 100% of ephrin-B2lacZ/lacZ
animals die within hours of birth due to VACTERL defects, ephrin-
B2ΔV/ΔV and ephrin-B26YFΔV/6YFΔV mice can be recovered as adults,
although many die before adulthood, presumably due to lung and
lymphatic defects (Makinen et al., 2005; Wilkinson et al., 2008). This
indicates that tyrosine phosphorylation of ephrin-B2 and the
transduction of ephrin-B2 reverse signaling through SH2 and PDZ
domain interactions are not necessary for the development and
septation of these midline structures.
A role for ephrin-B2 reverse signaling through PDZ domain
interactions in midline development did become apparent however
when ephrin-B2lacZ/+ and ephrin-B26YFΔV/+ mice were crossed to
generate ephrin-B2lacZ/6YFΔV mutant animals (Fig. 6C). The incidence
of hypospadias was signiﬁcantly greater in ephrin-B2lacZ/6YFΔV mu-
tants (86%) compared to that seen in ephrin-B2lacZ/+ littermates (16%)
(***Pb0.0001). A similar increase in the incidence of hypospadias was
found in parallel crosses generating ephrin-B2lacZ/ΔV mutants (71%)
(**P=0.0031). Because both ephrin-B2lacZ/6YFΔV and ephrin-B2lacZ/ΔV
mice present with increased hypospadias, it appears that PDZ domain
interactions through the C-terminal valine represent an important
component of ephrin-B2 reverse signaling in midline closure.
EphB2 forward signaling in midline septation does not require receptor
tyrosine kinase activity or PDZ domain interactions
Having also characterized roles for EphB2 forward signaling in
palate and urorectal development, we similarly attempted to identify
what elements of EphB2 forward signaling might be involved at the
midline by analyzing recently generated EphB2 forward signaling
mutant animals. These mice include EphB2VEV mutants, in which the
codons for the terminal three amino acids, valine–glutamate–valineFig. 3. Cleft palate in ephrin-B2lacZ mutants. (A) H&E stained coronal sections of WT and
ephrin-B2lacZ/lacZ E18 littermates. The ephrin-B2lacZ homozygote presents with a cleft
palate (*). (B) X-gal stained coronal sections from ephrin-B2lacZ/+ embryos at E12.5,
E13.5, and E14.5 detect expression of the ephrin-B2–β-gal fusion protein (blue).
Ephrin-B2 is expressed in the mesenchyme and leading epithelia of the palatal shelves
at E12.5 and E13.5 (*, left and middle) before palatal shelf closure. After adhesion,
ephrin-B2 expression is strongest in the midline epithelial seam (arrow, right). (C)
Coronal sections at E13.5 from WT and EphB2−/− embryos treated with anti-EphB2
antibody (top). EphB2 is expressed in the mesenchyme of the palatal shelf in theWT (*,
left), while no signal is detected in the mutant control. Coronal sections from an E14.5
EphB2lacZ/+ embryo stained with X-gal to show expression of the EphB2–β-gal fusion
protein (bottom) reveal that EphB2 becomes speciﬁcally expressed in the epithelia of
the palatal shelves, both immediately preceding (left) and at the site of adhesion
(right). (D) Coronal section from an E13.5 Tg-BAC-EphB3-YFP embryo treated with anti-
GFP antibody shows speciﬁc expression of EphB3 in the mesenchyme of the palatal
shelf (left). X-gal stained coronal sections from E13.5 and E14.5 Tg-BAC-EphB3-rtTA;
TRE-lacZ embryos treated with dox show EphB3 is initially highly expressed in the
mesenchyme of the palatal shelf at E13.5 (*, middle) but then becomes more
preferentially expressed in the leading epithelia as midline adhesion becomes
imminent (*, right). The expression of EphB3 is very similar to EphB2 and ephrin-B2.
(E) Coronal section from an E14 ephrin-B2lacZ/+ embryo treated with anti-EphB2 (left)
and anti-β-gal (middle) antibodies. The merged image (right) shows EphB2 and
ephrin-B2–β-gal are co-expressed on the midline epithelial seam where adhesion has
occurred.(VEV), were deleted to abolish interactions between EphB2 and PDZ
domain-containing proteins, EphB2K661R mutants, in which the lysine
residue at amino acid 661 was mutated to arginine to abolish the
tyrosine kinase catalytic activity of the EphB2 receptor, and EphB2KVEV
mutants, which combine both mutations to simultaneously lose PDZ
domain interactions as well as catalytic tyrosine kinase activity
(Genander et al., 2009). No urorectal malformation was found in
any of the EphB2VEV/VEV (n=107), EphB2K661R/K661R (n=102), or
EphB2KVEV/KVEV (n=202) mutant mice in an EphB3−/− background.
Further, all compound mutants were recovered as adults at expected
Mendelian ratios, indicating no neonatal lethality, and thus no cleft
palate phenotype. The data indicate EphB2 forward signaling in these
Fig. 4. Failed closure of the ventral abdominal wall in EphB2;EphB3 compound null
embryos. (A) Whole-mount image of an E18 EphB2−/−;EphB3−/− compound null
shows herniated visceral organs (*) due to failed abdominal body wall closure (left).
Transverse H&E stained section of an EphB2−/−;EphB3−/− E18 embryo similarly shows
failed midline closure of the ventral body wall and herniated visceral organs (*, right).
(B) Whole-mount BluO-gal stained EphB2lacZ/+ and EphB2+/+ embryos at E13.5 and
E15.5 to detect expression of the EphB2–β-gal fusion protein. EphB2 is expressed at the
ventral midline at E13.5 (arrows, top left) and at leading edges of the closing umbilical
ring at E15.5 (arrows, top right). No BluO-gal activity is detected in the WT embryos
that do not express the EphB2–β-gal fusion protein (bottom).
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molecules by the receptor tyrosine kinase domain or the interaction of
EphB2 with PDZ domain-containing proteins.
Ephrin-B2 reverse signaling through claudin at the midline
That ephrin-B2ΔV and ephrin-B26YFΔV mice do not phenocopy
ephrin-B2lacZ mice suggests (1) there is more to ephrin-B2 reverse
signaling than just SH2 domain interactions through phosphorylated
tyrosines and PDZ domain interactions through the C-terminus, and
(2) these non-canonical signaling avenues are critical elements of theTable 3
Incidence of omphalocele in EphB2;EphB3 compound mutants.
EphB2 mutation Background B2/B2;B3/B3 B2/+;B3/B3 +/+;B3/B3
EphB2− 129 38 (15) 63 (2) 42 (0)
EphB2lacZ 129 11 (1) 21 (0) 14 (0)
EphB2−/+;EphB3−/− (or EphB2lacZ/+;EphB3−/−) males were intercrossed with EphB2−/+;
EphB3−/− females (or EphB2lacZ/+;EphB3−/−) and offspring collected at E18.5. Animals
with defective ventral body wall closure are in parentheses.reverse signal employed for midline septation or closure. B-subclass
ephrins have been shown to interact with the claudins, a class of
tetraspan proteins known to directly mediate cell–cell adhesion
(Tanaka et al., 2005). To examine a potential role for the claudins in
ephrin-B2 reverse signaling, the expression of claudin-1 and claudin-4
(the two claudin molecules shown to associate with ephrin-B) was
investigated at the point of adhesion in the palate. Strikingly, IF shows
that both claudin-1 and claudin-4 are highly expressed in epithelia
directly before and right at midline cell–cell adhesion in the palate of
WT embryos (Fig. 7). This expression mimics the proﬁle of tyrosine-
phosphorylated ephrin-B, and indeed double IF shows that both
claudin and activated ephrin co-localize in adherent epithelia. These
data support a tyrosine phosphorylation-independent role for ephrin-
B2 reverse signaling involving the claudins in midline septation.
Discussion
The data presented here show that ephrin-B2lacZ/lacZ homozygotes
present with LTEC and cleft palate phenotypes, indicating novel roles
for ephrin-B2 reverse signaling in foregut septation and palatal shelf
closure. Moreover, we have shown that EphB2lacZ/lacZ;EphB3−/−
animals also present with cleft palate, indicating a role for EphB
forward signaling in midline fusion of the palate as well. The roles
identiﬁed here for both ephrin-B2 reverse signaling and EphB2
forward signaling in midline formation of the palate are remarkably
similar to what we previously reported for the tubularization of the
urethra and septation of the hindgut/cloaca into distinct urogenital
and anorectal compartments (Dravis et al., 2004). We also report here
that EphB2−/−; EphB3−/− compound null animals, but less so forward
signaling deﬁcient EphB2lacZ/lacZ; EphB3−/− animals present with
omphalocele. This indicates that closure of the ventral abdominal wall
occurs through EphB2/B3 acting primarily as ligands to stimulate
ephrin-B reverse signaling. Surprisingly, deconstruction of the ephrin-
B2 reverse signal and the EphB2 forward signal in these midline
structures using select point mutant mice indicates that these
bidirectional signals do not appear to require tyrosine kinase
phosphorylation events. Instead, the ephrin-B2 reverse signal can be
broken down into distinct tyrosine phosphorylation-independent
elements, one of which involves PDZ domain interactions, and the
other we propose involves interaction with claudin family tetraspan
molecules.
Fidelity of the lacZ alleles
A question to address in considering the data is the reliability of
our lacZ alleles that result in the synthesis of C-terminally truncated
proteins that lack their cytoplasmic domains and covalently attach β-
gal. This has been controversial given that similar animal models have
produced divergent claims about the physiological roles of forward
and reverse signaling events (Adams et al., 2001; Cowan et al., 2004).
Therefore, we would like to point out that (1) the ephrin-B2–β-gal
fusion protein encoded by the ephrin-B2lacZ allele localizes properly to
the cell surface and clusters into higher order oligomers, unlike other
ephrin-B2 unconjugated C-terminal cytoplasmic truncations which
become trapped in the trans-Golgi network and do not trafﬁc to the
plasma membrane (Cowan et al., 2004), and can properly activate
forward signaling through EphB receptors (Supplemental Fig. 1); (2)
the success of the lacZ alleles to properly signal non-cell autono-
mously has been demonstrated in vivo now several times over, as the
ephrin-B3lacZ/lacZ mutant does not present with locomotor defects in
the spinal cord associated with the ephrin-B3−/− protein null
(Yokoyama et al., 2001), the ephrin-B2lacZ/lacZ mutant does not result
in early embryonic lethality due to vascular angiogenic failures
associated with either ephrin-B2−/− protein null or ephrin-B2
unconjugated C-terminal truncation mice (Adams et al., 2001;
Cowan et al., 2004), and EphB2lacZ/lacZ mutants do not exhibit axon
Fig. 5. Ephrin-B is tyrosine phosphorylated at the point of midline septation and closure in the foregut and palate. (A) Coronal sections from E10.5 WT embryos stained with an
antibody that recognizes speciﬁc phosphorylation of tyrosines 324 and 329 (top) or of tyrosine 317 (bottom) on the conserved cytoplasmic tail of ephrin-B molecules to detect
reverse signaling activity in vivo. Both antibodies detect tyrosine-phosphorylated ephrin-B on the endoderm before (left) and during septation (middle). Activated ephrin-B also
appears in the mesenchyme ﬂanking the site of septation (*). Adjacent sections pre-treated with λ-phosphatase conﬁrm antibody speciﬁcity (right). (B) Adjacent coronal sections
from an E14 ephrin-B2lacZ/+ embryo treated with anti-β-gal (left) or anti-phospho-ephrin-BY324/Y329 (right) antibodies. While ephrin-B2 is expressed in both the mesenchyme and
leading epithelia of the palatal shelf (left), it is only the ephrin in the leading epithelia that is tyrosine phosphorylated (right). (C) Coronal section from aWT E14 embryo treated with
anti-EphB2 (left) and anti-phospho-ephrin-BY324/329 (middle) antibodies. EphB2 is co-expressed with tyrosine-phosphorylated ephrin-B in leading epithelia of the palatal shelves.
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Fig. 6. New ephrin-B2 reverse signaling point mutant mice identify separate tyrosine phosphorylation-independent components of ephrin-B reverse signaling at the midline.
(A) Targeting strategy for the generation of the ephrin-B2ΔV allele (N=NcoI). (B) Summary of the expected consequences on signaling for the ephrin-B2lacZ, ephrin-B26YFΔV, and
ephrin-B2ΔV alleles. (C) Incidence of urorectal malformation in male progeny following crosses between ephrin-B2lacZ/+ males and either ephrin-B26YFΔV/+ or ephrin-B2ΔV/+ females,
compared to the 100% incidence found in ephrin-B2lacZ/lacZ animals.
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Fig. 7. Claudin-1 and claudin-4 are co-expressed with activated ephrin-B and EphB2 at the point of midline adhesion in the palate. (A) Coronal section from aWT E14 embryo treated
with anti-claudin-4 (green) and phospho-ephrin-BY324/Y329 (red) antibodies reveal both molecules are expressed in adherent epithelia of the palatal shelves. (B) Coronal section
from aWT E14 embryo treated with anti-claudin-4 (green) and phospho-ephrin-BY317 (red) reveals the same co-expression after adhesion has been initiated. (C) Adjacent sections
from a WT E14 embryo treated with anti-claudin-1 (left) and phospho-ephrin-BY317 (right) reveal claudin-1 is also present in the adherent palatal epithelia with tyrosine-
phosphorylated ephrin-B.
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et al., 2000; Cowan et al., 2004; Henkemeyer et al., 1996); (3) the lacZ
alleles do not hyperactivate forward signaling, as genetic assays have
shown (Dravis et al., 2004), and as is suggested by the fact that
EphB2F620D mice with hyperactive EphB2 forward signals (Holmberg
et al., 2006) do not present with any midline defects (data not
shown); and (4) the cell autonomous defects seen with the lacZ
alleles have also been found in traditional germline knockout animals
for EphB and as well as the targeted mutations of ephrin-B26YFΔV and
ephrin-B2ΔV now, further conﬁrming that the midline defects
characterized in lacZ mice are not the result of hypermorphic or
neomorphic activity.
Midline EphB:ephrin-B bidirectional signaling operates independently of
tyrosine phosphorylation
One of the most interesting ﬁndings in our data is that ephrin-
B26YFΔV/6YFΔV mice do not phenocopy ephrin-B2lacZ/lacZ mice, which is
surprising because both alleles block canonical signaling structures of
the ephrin-B cytoplasmic domain: phosphorylated tyrosines thatserve as a substrate for SH2 domain docking and a C-terminal valine
that interacts with PDZ domains. This indicates that signaling through
these two elements is not necessary in the midline septation events
we have linked to ephrin-B reverse signaling. However, by combining
the ephrin-B26YFΔV and ephrin-B2ΔV alleles with ephrin-B2lacZ, to
produce ephrin-B2lacZ/6YFΔV and ephrin-B2lacZ/ΔV mice, and comparing
those animals to ephrin-B2lacZ/+ animals (Fig. 6C), it becomes
apparent that PDZ domain interactions through the C-terminus of
ephrin-B2 do contribute to these midline events. The disconnect
between the ephrin-B2lacZ and ephrin-B26YFΔV or ephrin-B2ΔV alleles
suggests there are alternate avenues of reverse signaling through
ephrin-B that are independent of SH2/PDZ domain interactions, but
nonetheless still necessary for proper midline development.
Other groups have identiﬁed potential non-canonical signaling
avenues that may be of relevance here. These include the discovery
that the ephrin-B cytoplasmic tail is serine phosphorylated, that a
P-P-Q-S-P motif on the cytoplasmic tail can mediate SH3 domain
interactions, that Dishevelled can constitutively interact with the
ephrin-B cytoplasmic tail in Xenopus, and that ephrin-Bs can interact
with claudins (Essmann et al., 2008; Segura et al., 2007; Tanaka et al.,
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interesting, as it could explain why our genetic studies indicate no
apparent role for ephrin-B2 tyrosine phosphorylation in midline
septation, even though our expression data clearly demonstrate that
ephrin-B is tyrosine phosphorylated precisely at the adhesion sites
where septation takes place. Reverse signaling might still occur in the
absence of ephrin-B tyrosine phosphorylationwith our ephrin-B26YFΔV
mice, if a key adaptor protein like Grb4 could simply ﬁnd itself
recruited to the ephrin cytoplasmic tail through one of its three SH3
domains, instead of its SH2 domain, to produce similar physiological
outcome at the midline. The ephrin-B SH3 and SH2 domain binding
motifs might therefore possess some redundancy that masks their
importance in midline signaling.
However, given the nature of the defects in midline septation and
closure that are characterized in our mice here, it is the interaction
between the ephrins and claudins that we ﬁnd of particular interest.
The claudins have been characterized to directly mediate adhesion
between cells through high-afﬁnity interactions involving their
extracellular loops, and the interaction between ephrin-B and claudin
has been shown to modulate this epithelial adhesion, albeit in
regulating paracellular ﬂow (Tanaka et al., 2005). This suggests that
the interaction between ephrin-B2 and claudins might regulate the
adhesiveness of epithelia coming into contact at the midline, and
indeed we ﬁnd that both claudin-1 and claudin-4 are highly co-
localized with ephrin-B2 and EphB2 on the cell surface of adhering
epithelial cells in the palate. Of note, claudin expression does not
appear restricted to its more canonical tight junction localization,
which is visualized as distinct puncta, but instead appears to be
expressed across the breadth of the epithelial cell surface. Based on
this expression, we strongly suspect that ephrin–claudin interactions
represent a tyrosine phosphorylation-independent portion of ephrin-
B reverse signaling in these midline septation events, perhaps in
mediating the actual cell–cell adhesion of these lateral structures.
On the other side of the bidirectional signal, it is also interesting
that forward signaling through the EphB2 receptor appears to require
neither the tyrosine kinase catalytic activity of the receptor nor the
C-terminal PDZ-binding motif in these midline structures. This is less
surprising than our ﬁndings with reverse signaling, however. Even
without tyrosine kinase activity, EphB2 can still be phosphorylated on
critical tyrosine residues by intracellular molecules such as Abl, Src
family kinases, or co-expressed Eph receptors in much the same way
the kinase-dead Eph receptor EphB6 activates forward signaling
(Freywald et al., 2002; Vindis et al., 2003; Yu et al., 2001). Further,
EphB2 is a large molecule with numerous protein interaction sites
that were untouched by our targeted mutations (notably including
the juxtamembrane tyrosines and SAM domain), which could play
important roles in the forward signaling element involved in midline
development.
EphB/ephrin-B signaling in midline cell–cell adhesion
Our genetic analyses indicate critical roles for ephrin-B reverse
signaling in multiple septation events at the embryonic midline. What
then is the ephrin-B reverse signal doing in these structures? Our
analysis of where ephrin-B reverse signaling is localized by utilizing IF
is very useful here, as it demonstrates that both ephrin-B tyrosine
phosphorylation (representing activated ephrin-B) and claudin
speciﬁcally localize to the leading epithelia at the sites where cell
adhesion initiates septation and closure. In addition, EphB2 and EphB3
are also expressed and likely actively signaling in the same midline
epithelia. These epithelial cells are not necessarily proliferative or
migratory; their principal function is to adhere to adjacent epithelia at
the point of septation. When we couple the failure of midline
structures to properly adhere in forward and reverse signaling
deﬁcient animals with this expression data localizing EphB, ephrin-
B, and the adhesion regulatory molecule claudin to sites of celladhesion, it appears that these bidirectional signals might be
responsible for producing a cell adhesion outcome in these midline
septation events. This is an exciting hypothesis that will need to be
addressed through future analyses of the behavior of these cells in vivo
and in cell culture assays.
How then might the Ephs and ephrins produce a cell–cell adhesion
response? This continues to be a confounding question, trying to
determine how in one instance these molecules can provoke a cell
repulsion response and in others lead to cell adhesion. An emerging
answer is that Eph–ephrin reverse signaling produces a cell adhesion
response the same way it produces a cell repulsion response—through
modulating the balance of activity in the Rho family GTPases Rho, Rac,
and Cdc42. Both forward and reverse signal transductions function to
regulate these Rho-family GTPases, and subtle shifts in the relative
activity of these molecules (through differential activation or antago-
nistic crosstalk) can produce different cytoskeletal behavior consistent
with either cell adhesion or cell repulsion outcomes (Burridge and
Doughman, 2006; Jaffe and Hall, 2005).
The link between ephrin reverse signaling and Rho family GTPases
is potentially interesting given that the activation of these molecules
has been linked to the production of ﬁlopodia-like extensions, which
facilitatemidline adhesion in Drosophila dorsal closure, a paradigm for
the epithelial adhesion events discussed here (Jacinto et al., 2000).
This presents the intriguing hypothesis that ephrin-B reverse
signaling might become activated in these adherent epithelia,
producing activated combinations of Rho/Rac/Cdc42 that then elicit
ﬁlopodia-like extensions in these cells; these ﬁlopodia then extend
across themidline to establish initial sites of contact between adjacent
cells that rapidly mature into adherens junctions to zip these midline
structures closed. Eph–ephrin regulation of ﬁlopodia generation and
motility has previously been shown to be important in synaptic
development, particularly for the generation of dendritic spines,
suggesting some potential functional redundancy in these very
different structures (Klein, 2009). For the PDZ-dependent aspect of
midline ephrin signaling identiﬁed in our new ephrin-B2ΔV mice, this
might involve the documented interaction of ephrin-B with PAR-3,
which targets Rho family molecules through its complex with PAR-6
and aPKC (Lin et al., 1999; Nishimura et al., 2005). For the tyrosine
phosphorylation- and PDZ-independent signaling avenues suggested
by the mice, this might involve Grb4 docking via the ephrin-B SH3
domain or the association of ephrin-B with Dishevelled, both of which
are linked to Rho family GTPase activity (Segura et al., 2007; Tanaka
et al., 2003).
It is less clear how ephrin and claudin might work together to
mediate midline adhesion. This interaction is not thought to require
the cytoplasmic tail of ephrin, so it is possible that differential
clustering of WT ephrin-B2 and the ephrin-B2–β-gal fusion protein
might somehow alter the respective interactions of the ephrin with
claudin, resulting in compromised midline adhesion in ephrin-B2lacZ
animals. Future biochemical analyses must aim to address the nature
of this ephrin–claudin interaction, how it might function to control
cell adhesion, and how this process may fail in our mutant animals.
Our data differ with other studies proposing how Eph–ephrin
signaling can produce cell adhesion. It has been suggested that cell
adhesion is a more passive outcome that takes place through the
inhibition of canonical repulsive Eph–ephrin signaling, either through
cis-inhibition on co-expressing cells (Carvalho et al., 2006; Yin et al.,
2004), or through inhibitory splice variants (Holmberg et al., 2000).
Our work demonstrates that midline epithelia are actively transduc-
ing reverse signals, suggesting that B-subclass ephrins are eliciting an
active adhesion response, not just inhibiting cell repulsion to permit
adhesion. It has also been suggested that the Ephs and ephrins are
themselves adhesion molecules, and cell repulsion occurs when the
interaction of these cell-surface receptors is broken, either by
endocytosis or by a protease (Marston et al., 2003; Zimmer et al.,
2003). This model is not consistent with our observations because the
Table 4
Overlap between VACTERL association defects and malformations found in EphB/ephrin-B mutant mice.
VACTERL association defects Eph/ephrin involved Defect References
Vertebral Ephrin-B1 Asymmetric rib attachment Compagni et al.(2003)
Ephrin-B2 Abnormal somite patterning Davy and Soriano(2007)
Anorectal EphB2,EphB3 Failed cloacal septation leading to persistent cloaca with GI ﬁstula Dravis et al.(2004)
Ephrin-B2
Cardiac Ephrin-B2 Enlarged cardiac valves Cowan et al.(2004)
Tracheoesophageal Ephrin-B2 Tracheoesophageal ﬁstula with esophageal atresia This manuscript
Renal Ephrin-B2 Hydronephrosis due to failed ureter–bladder integration Unpublished data
Limb Ephrin-B1 Polydactyly Compagni et al.(2003)
Davy et al.(2004)
Peripheral VACTERL defects Eph/ephrin involved References
Hypospadias EphB2,EphB3 Dravis et al.(2004)
Ephrin-B2
Cleft palate EphB2,EphB3 Orioli et al.(1996)
Compagni et al.(2003)
Ephrin-B1 ephrin-B2 Davy et al.(2004)
This manuscript
Omphalocele EphB2,EphB3 Compagni et al.(2003)
Ephrin-B1 Orioli et al.(1996)
This manuscript
Neural tube closure EphA7 Holmberg et al.(2000)
Ephrin-A5
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left intact and are able to trafﬁc to the plasma membrane, where they
should be able to still perform as non-signaling cell adhesion
molecules. And yet, as the data show, mice with these truncated
alleles present with the same, if not more severe, adhesion defects as
the null mutants. This further supports an active signaling role for the
Ephs and ephrins in promoting cell adhesion.
EphB/ephrin-B signaling and the VACTERL association
VACTERL refers to an association of embryonic malformations
comprisedof vertebral (V), anorectal (A), cardiac (C), tracheoesophageal
(TE), renal (R), and limb (L) abnormalities, that often presents
with additional anomalies such as hypospadias, cleft palate, neural
tube defects, and omphalocele. Here we ﬁnd that animals with EphB/
ephrin-B signaling ablations present with LTEC, cleft palate, and
omphalocele, which represent one of the deﬁning features of VACTERL
as well as two associated anomalies. These data extend upon previous
studies demonstrating that Eph/ephrin signaling disruptions cause
anorectal malformations and hypospadias (Dravis et al., 2004), cardiac
defects (Cowan et al., 2004), limb and skeletal abnormalities (Compagni
et al., 2003), and neural tube defects (Holmberg et al., 2000). We have
alsonoticedadistended kidneyphenotype in ephrin-B2lacZmice, due to a
defect in ureter–bladder integration (unpublished data), suggesting
links to renal development as well. This striking overlap between EphB/
ephrin-B malformations and VACTERL association (Table 4) leads us to
propose Eph/ephrin signaling as a molecular basis for the association.
This extends our knowledge of VACTERL from morphogens like Shh to
cytoskeletal regulators like the Ephs and ephrins, which are likely
directly responsible for guiding the cell–cell interactions, movements,
and adhesion events that are disrupted in affected individuals.
Methods
Animals
EphB2 (Henkemeyer et al., 1996), EphB3 (Orioli et al., 1996),
EphB2VEV, EphB2K661R and EphB2KVEV (Genander et al., 2009), ephrin-
B26YFΔV (Thakar et al., unpublished data), and ephrin-B2lacZ (Dravis et al.,
2004) mice have been described. The EphB2 and EphB3mutations have
been maintained on an inbred 129 background and have also beenbackcrossed to theCD1 strain. All ephrin-B2mutantsweremaintained on
a mixed 129/CD1 background. Induction of the tet-on system was
achieved by supplying pregnant femaleswith drinkingwater containing
0.5 mg/ml doxycycline and 5% sucrose for 16–24 hours. Statistical
comparisons utilized the two-tail Fischer's extract test.
Generation of Tg-BAC-EphB3-YFP and ephrin-B2ΔV animals
Tg-BAC-EphB3-YFP mice contain a destabilized variant of eYFP
knocked into the ORF of BAC EphB3 sequences. Transgenic mice were
generated from BAC clone RP23-213M14, a 208 kb BAC from a C57BL/
6J background containing 42 kb upstream of the EphB3 start codon,
that was purchased from the BACPAC resources center at the Children's
Hospital Oakland.D2eYFP-1 (Clontech)was targeted into the EphB3ORF
in RP23-213M14 using bacterial homologous recombination (http://
web.ncifcrf.gov/research/brb/recombineeringInformation.aspx).
Targeting was conﬁrmed by PCR and restriction digests. Pronuclear
injection was performed by Transgenic Core facilities at the UTSW
Department of Developmental Biology. To construct the targeting
vector for ephrin-B2ΔV, RP23-328F4 was purchased from the same
BACPAC resources center. This BAC contains ephrin-B2 exon 5, which
has the sequences coding for the cytoplasmic tail. Through bacterial
homologous recombination, the ephrin-B2 exon 5 was targeted to
delete the GTC codon for valine at the ephrin-B2 C-terminus and
insert a LoxP-ﬂanked NeoR cassette 27 bp downstream of the stop
codon. Insertion of the LoxP site results in a 53 bp deletion of 3′ non-
coding sequence downstreamof the stop codon,GACCTGC…GGACTGC.
Bacterial homologous recombination was then performed on the
modiﬁed BACwith a capture vector containing 5′Diphtheria toxin and
3′ HSV-tk selection markers to produce a targeting vector with a
6.1 kb 5′ homology arm and an 11.9 kb 3′ homology arm. The
targeting vector was linearized through AscI digestion and electro-
porated into ES cells, with cell lines screened through Southern blot
analysis with 5′ and 3′ external probes to detect proper homologous
recombination. Blastocyst injection was performed with two of the
positive cell lines to generate chimeric mice through the UTSW
Transgenic Core Facility, and germline transmissionwas conﬁrmed. The
LoxP-ﬂanked cassette was removed with a germline Krox20-Cre line.
Protein expression was conﬁrmed by immunoblotting protein lysates
from E12.5 embryos with an antibody recognizing the N-terminus of
ephrin-B2 (Novus Biologicals).
150 C. Dravis, M. Henkemeyer / Developmental Biology 355 (2011) 138–151Immunoﬂuorescence
Immunoﬂuorescence was performed as described (Dravis et al.,
2004). As a phosphotyrosine control sections were treated with λ-
protein phosphatase (NEB) for 45 minutes prior to primary applica-
tion. Primary antibodies used were goat anti-EphB2 (R&D Systems),
rabbit anti-β-Gal (Cappel), rabbit anti-phospho-ephrin-B (Cell Sig-
naling Technology), rabbit anti-phospho-ephrin-B [Tyr298] recogniz-
ing mouse Y317 (Novus Biologicals), rabbit anti-ephrin-B1 (C-18,
Santa Cruz), rabbit anti-GFP (Molecular Probes), rabbit anti-claudin-1
(Invitrogen) and Alexa Fluor 488-conjugated claudin-4 (Invitrogen).
Secondary antibodies were Cy2 donkey anti-goat, Cy3 donkey anti-
rabbit, and Cy2 donkey anti-rabbit (Jackson ImmunoResearch).
Images were visualized on a Zeiss 510 LSM confocal microscope.
Histochemical β-gal staining
X-gal and BluO-gal stains were performed as described (Dravis
et al., 2004) and counterstained with nuclear fast red. Whole-mount
embryos were dehydrated through sequential ethanol washes and
cleared in methyl salicylate.
EphB2 tyrosine phosphorylation detection
Protein lysates from the heads of E13.5 embryos were dissociated
mechanically in lysis buffer (30 mM Hepes pH 7.5, 150 mM NaCl, 10%
glycerol, 1.5% Triton-X 100, 1 mM EGTA, 10 mM sodium pyrophos-
phate, 10 mM NaF, 1 mM sodium orthovanadate, 1 mM PMSF, and
protease inhibitor cocktail), immunoprecipitated with an antibody
against EphB2 (R&D Systems), separated by SDS-PAGE, and immuno-
blotted with antibodies against EphB2 or phosphotyrosine (Upstate
Biotechnology).
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